KRR1 small subunit processome componentGenealiases: HRB2 · RIP-1
Q-omics provides the consensus-scored KRR1 profile across patient tissues and cancer cell-line models. KRR1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KRR1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, KRR1 protein abundance shows 33,490 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, THCA, and GBM as cancer lineages where KRR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRR1 survival associations across molecular data types. KRR1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRR1 RNA expression–survival associations across cancer types. High KRR1 expression shows unfavorable associations in LIHC, UVM and LUAD, but favorable associations in KIRC, LUSC and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KRR1 RNA expression.
This table summarizes KRR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KRR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRR1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, COAD and BLCA. The THCA box plot shows higher KRR1 RNA expression in normal versus tumor tissue (log2 FC = −0.512, t-test p < 0.001).
This table shows molecular features associated with KRR1 in patient tissues and cancer cell lines. In patient samples, KRR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
